BC028528 Inhibitors
The BC028528 Inhibitors can be broadly categorized based on the different cellular signaling pathways they are designed to interact with. These inhibitors serve as valuable tools to dissect the role and involvement of BC028528 in those respective pathways. For instance, Imatinib and Erlotinib are tyrosine kinase inhibitors that can affect BC028528 if the protein has a direct or indirect relationship with the receptor tyrosine kinases or downstream elements in this pathway. On the other hand, Palbociclib, a cyclin-dependent kinase inhibitor, would interfere with BC028528's function if it is connected to cell cycle regulation.
Other inhibitors like Thapsigargin and Blebbistatin serve to elucidate involvements of BC028528 in calcium homeostasis and cytoskeletal dynamics, respectively. The chemical compounds Axitinib, targeting VEGFR, and Sorafenib, targeting Raf kinase, offer additional avenues for understanding the role of BC028528 in angiogenesis and MAPK signaling. Overall, this collection of inhibitors spans multiple pathways, providing a multi-faceted approach to decoding BC028528's cellular functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Tyrosine kinase inhibitor that can inhibit BC028528 if it directly or indirectly interacts with tyrosine kinases. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Targets mTOR; can inhibit BC028528 if the protein is involved in the mTOR pathway, either upstream or downstream. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
EGFR inhibitor; targets BC028528 if it interacts with the EGFR signaling pathway, either directly or indirectly. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Broad-spectrum kinase inhibitor; can target BC028528 if the protein modulates or is modulated by kinases. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Cyclin-dependent kinase inhibitor; inhibits BC028528 if the protein is involved in cell cycle regulation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Another EGFR inhibitor; could inhibit BC028528 if it interacts with the EGFR signaling pathway. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor; targets BC028528 if it has a role in calcium homeostasis. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Raf kinase inhibitor; can inhibit BC028528 if the protein is involved in Raf/MAPK signaling. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Inhibits myosin II ATPase; could affect BC028528 if it is involved in cytoskeletal reorganization. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
Nuak1 inhibitor; inhibits BC028528 if involved in AMPK-related pathways. | ||||||